GLP-1 |
Reduction of body weight by about 1.9% (in T2DM patients [107]
Enhanced sense of fullness [108]
Increase insulin secretion [109]
|
|
Can only be
given subcutaneously
[110] |
Liraglutide
(a GLP-1
analogue)
|
Action depends on glucose level
Increases satiety
Enhance regeneration of new beta cells
Decreases plasma lipid level
Long half life
[37], [38] |
|
Can only be given subcutaneously
Thyroid C-cell cancer risk [111]
Cancer risk disputed in human [112]
|
Albiglutide
(a GLP-1
analogue) |
|
[47, 48] |
Can only be
given subcutaneously [110] |